Using aspirin to prevent heart disease in patients with high lipoprotein(a) levels
Aspirin for Primary Prevention of Cardiovascular Disease in Patients with Elevated Lipoprotein(a)
This study is looking at whether taking a small daily dose of aspirin can help prevent heart problems for people who have high levels of a fat called lipoprotein(a), which is linked to a greater risk of heart disease, and it aims to include a variety of people to make sure the results are helpful for everyone.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-10904971 on NIH RePORTER |
What this research studies
This research investigates whether daily low-dose aspirin can help prevent cardiovascular disease in individuals with elevated levels of lipoprotein(a), a lipid particle linked to increased heart disease risk. The study will analyze data from previous trials involving diabetic and elderly participants to see how aspirin affects heart disease events based on lipoprotein(a) levels. Additionally, it aims to include diverse populations to ensure the findings are applicable to a broader group of patients. By examining stored blood samples, the research seeks to provide insights into the potential benefits of aspirin therapy for this specific patient group.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with elevated lipoprotein(a) levels who are at risk for cardiovascular disease.
Not a fit: Patients without elevated lipoprotein(a) levels or those who already have established cardiovascular disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could offer a new preventive treatment option for patients at high risk of cardiovascular disease due to elevated lipoprotein(a) levels.
How similar studies have performed: Previous studies have shown promising results regarding the use of aspirin for cardiovascular prevention, but this specific approach focusing on lipoprotein(a) is relatively novel.
Where this research is happening
La Jolla, United States
- University of California, San Diego — La Jolla, United States (Active)
Researchers
- Principal investigator: Bhatia, Harpreet Singh — University of California, San Diego
- Study coordinator: Bhatia, Harpreet Singh
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.